Neuroleptic malignant syndrome (NMS): recognition and management

What NMS is

NMS is a hyperdopaminergic-blockade state driven by sudden reduction in dopamine signaling. The mechanism is thought to be D2 blockade in the hypothalamus (temperature dysregulation), striatum (muscle rigidity), and other nuclei that regulate autonomic function.

Classic tetrad:

• Hyperthermia (usually above 38.5 °C, often above 40 °C)
• Lead-pipe muscle rigidity (generalized, hypertonic without cogwheeling)
• Altered mental status (confusion, delirium, stupor, coma)
• Autonomic instability (labile blood pressure, tachycardia, diaphoresis, tachypnea)

Plus laboratory findings: markedly elevated CK (often 10,000 to 100,000 IU/L), leukocytosis, elevated liver enzymes, myoglobinuria, and in severe cases DIC, AKI, and multi-organ failure.

Onset and time course

NMS typically develops over 1 to 3 days after starting an antipsychotic, increasing a dose, or switching to a higher-potency drug. Some cases evolve over up to 2 weeks. Once established, the syndrome usually persists for 7 to 10 days after the offending drug is stopped, longer if a depot antipsychotic (LAI) was the trigger since the drug is not rapidly cleared.

Which drugs cause NMS

Antipsychotics are the main class. Any antipsychotic can cause NMS, but high-potency first-generation drugs (haloperidol, fluphenazine) carry the highest risk. Second-generation drugs have lower rates but real cases occur with all of them, including aripiprazole and clozapine. Depot LAIs are particularly concerning because clearance is slow after stopping.

Non-psychiatric dopamine antagonists:

• Metoclopramide (Reglan), especially with prolonged use
• Prochlorperazine (Compazine)
• Promethazine (Phenergan)
• Droperidol

Abrupt withdrawal of dopamine agonists in Parkinson's disease patients can produce a similar syndrome (parkinsonism-hyperpyrexia syndrome, essentially NMS).

Cobenfy (xanomeline-trospium) does not block D2 receptors and does not cause NMS. See our Cobenfy state of practice.

Risk factors

• Male sex (2:1 male predominance)
• Younger age (peak incidence 20 to 40)
• Dehydration and heat exposure
• Rapid dose escalation
• Parenteral administration (particularly IM haloperidol at high doses)
• Prior NMS episode (roughly 30 percent recurrence risk with rechallenge)
• Depot LAIs (harder to reverse once syndrome starts)
• Catatonia (may mimic and predispose)
• Withdrawal of anti-Parkinson drugs

Distinguishing from serotonin syndrome

The two are often confused because both produce fever, autonomic instability, and altered mental status. Key differences:

See our serotonin syndrome page for the counterpart.

Management

Immediately stop the offending antipsychotic. Do not attempt to continue treatment.

Supportive care:

• ICU admission for moderate to severe cases
• Aggressive cooling (cooling blankets, ice packs, IV fluids)
• IV fluids for rhabdomyolysis and to maintain renal perfusion
• Correction of electrolyte abnormalities
• Mechanical ventilation if respiratory failure
• Dialysis for AKI or severe rhabdomyolysis

Pharmacologic treatment for moderate to severe cases:

• Bromocriptine 2.5 mg PO/NG every 8 hours, titrated to 5 to 10 mg every 6 hours. D2 agonist reverses the dopamine blockade.
• Dantrolene 1 to 2.5 mg/kg IV every 6 hours for severe rigidity and hyperthermia. Skeletal muscle relaxant that reduces heat production.
• Amantadine 100 to 200 mg PO/NG twice daily as an alternative.
• Benzodiazepines (lorazepam 1 to 2 mg IV/IM every 4 to 6 hours) for agitation and possibly for symptom reduction.

Electroconvulsive therapy (ECT) is sometimes used for refractory cases and shows real efficacy.

Avoid:

• Anticholinergics (do not help and may worsen hyperthermia)
• Antipyretics (do not work; the fever is muscle-driven)
• Bromocriptine/dantrolene combination is often used, though evidence for combination benefit is limited

Rechallenge after recovery

If antipsychotic treatment is still needed after NMS recovery, rechallenge is possible but risky (about 30 percent recurrence). Practical framework:

• Wait at least 2 weeks after full symptom resolution
• Choose a low-potency second-generation drug (quetiapine, aripiprazole, or Cobenfy would be lowest-risk)
• Start at very low dose and titrate slowly
• Consider clozapine if psychosis is the indication and other drugs failed (NMS with clozapine is rare)
• Monitor closely for early NMS signs

Consultation with psychiatry pharmacy is often appropriate for rechallenge planning.

Common questions

How rare is NMS? Estimated 0.02 to 3 percent of patients treated with antipsychotics. Rate has decreased over the last 40 years with second-generation drugs and better recognition. Absolute number of cases remains substantial given the volume of antipsychotic prescribing.

Can NMS happen with atypical antipsychotics? Yes. Aripiprazole, olanzapine, quetiapine, risperidone, clozapine have all been reported. Rates are lower than first-generation drugs but not zero.

What is the mortality of NMS? About 10 to 20 percent with modern treatment. Higher in delayed recognition, older patients, comorbid dehydration, and severe rhabdomyolysis with renal failure.

Can you die from mild NMS? Mild cases (temperature below 38.5 °C, mild rigidity, no organ failure) usually recover fully with drug discontinuation and supportive care. Progression from mild to severe can happen if the drug is not stopped, which is why early recognition is important.

Should a patient with prior NMS ever take an antipsychotic again? Sometimes yes. About 30 percent of rechallenge cases recur, meaning 70 percent do not. Rechallenge with a different, low-potency drug at low dose is often necessary for patients with schizophrenia. The decision is individual and typically involves psychiatric pharmacy consultation.

How is NMS different from malignant hyperthermia? Malignant hyperthermia is a genetic disorder of muscle calcium handling triggered by volatile anesthetics or succinylcholine. It produces similar hyperthermia and rigidity. Dantrolene is the specific antidote for both. NMS is triggered by dopamine antagonists in the CNS, not by anesthetics.

Is catatonia related? Catatonia and NMS overlap phenomenologically. Some cases labeled NMS may be catatonia triggered or worsened by antipsychotic exposure. Lorazepam is diagnostic and therapeutic for catatonia. If a patient with catatonic features develops NMS on an antipsychotic, benzodiazepines plus ECT are often used.

Sources

• Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6):870-876.
• Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist. 2011;1(1):41-47.
• Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77(1):185-202.
• Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs. 2009;23(6):477-492.
• Woodbury MM, Woodbury MA. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry. 1992;31(6):1161-1164.